2 Information about osimertinib
2.1 Osimertinib (Tagrisso, AstraZeneca) is indicated 'for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations'.
2.2 The dosage is 80 mg taken orally once daily until disease progression or unacceptable toxicity. EGFR mutation status in tumour or plasma specimens should be determined using a validated test method. Dosing interruption with or without dose reduction may be needed based on individual safety and tolerability. If dose reduction is necessary, then the dose should be reduced to 40 mg once daily.